To everything there is a season, and a
time to every purpose under the heaven.

~ Ecclesiastes 3

Time changes everything. In response,
we adapt. Psychiatry is no exception.
Our field is on the cusp of monumental changes, from understanding genes and
gene expression to microRNA, mitochondria,
neuronal and microglia functions, synaptic
pruning, functional brain connectivity, behav-
ior, development, the transduction of stress to
neurobiology, how we make decisions, how we
make emotions, how we make narratives, and
how we can relieve suffering with psychother-
apy, psychopharmacology, devices, and lifestyle
interventions. To help clinicians make sense of
these changes, *Psychiatric Annals* will continue
to evolve. We will provide new peer-review
and psychiatric news sections, as well as wel-
come submissions of clinically relevant original
research, reviews, case reports, and feature ar-
ticles. We will continue the tradition of provid-
ing informative continuing medical education
(CME) to inform clinical practice.

To everything there is a season and it is time
to give thanks to the Editorial Board under the
editorship of Dr. Jan Fawcett for their service.
*Psychiatric Annals* is bringing on a new Editorial
Board to give more people the opportunity to
serve. I thank them in advance for their future
ccontributions.

Dr. Fawcett served as the Editor of *Psychiatric
Annals* for 25 years. With his wisdom, he saw
the journal as a way to help clinicians learn an
area in depth by organizing the issues themati-
cally. Each issue has reviews centered on mul-
tiple aspects of a single theme. Feedback from
readers (and there are about 36,000 of you) has
been broadly positive. Along with the long-
standing Editorial Board, as well as too many
authors and guest editors to count and thank,
the journal has provided mental health profes-
sionals with clinically relevant information. We
all owe a debt of gratitude to Jan for all of his
years of service and giving. He has passed the
Editor baton to me, for which I am grateful and
humbled. I would also especially like to thank
Dr. Lenard A. Adler for agreeing to be the
CME Editor and for bringing his expertise on
attention-deficit/hyperactivity disorder, clinical
trials, and psychopharmacology.

As we move forward, please let me know
your thoughts, comments, critiques, sugges-
tions, and, yes, even praises if you feel so moved.
I look forward to hearing from you.

Andrew A. Nierenberg, MD holds the
Thomas P. Hackett, MD, Endowed Chair in
Psychiatry at MGH, and is the Director of the
Dauten Family Center for Bipolar Treatment In-
novation, and the Director, Center for Clinical
Research Education, MGH Research Institute,
Massachusetts General Hospital; and a Profes-
sor of Psychiatry, Harvard Medical School.

Address correspondence to Andrew A.
Nierenberg, MD, via email: psyann@Healio.com.
doi:10.3928/00485713-20180328-01